

Review – Prostate Cancer

Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review

Koen Degeling^{a,b}, Amanda Pereira-Salgado^{a,b}, Niall M. Corcoran^{c,d,e}, Paul C. Boutros^{f,g,h,i,j}, Peter Kuhn^{k,l,m}, Maarten J. Ijzerman^{a,b,n,o,*}

^a Cancer Health Services Research, Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia; ^b Cancer Health Services Research, Centre for Health Policy, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia; ^c Department of Urology, Frankston Hospital, Frankston, Australia; ^d Department of Surgery, The University of Melbourne, Melbourne, Australia; ^e Division of Urology, Royal Melbourne Hospital, Melbourne, Australia; ^f Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA, USA; ^g Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA; ^h Jonsson Comprehensive Cancer Centre, University of California, Los Angeles, Los Angeles, CA, USA; ⁱ Departments of Human Genetics and Urology, University of California, Los Angeles, Los Angeles, CA, USA; ^j Department of Medical Biophysics, University of Toronto, Toronto, Canada; ^k USC Michelson Center for Convergent Biosciences, University of Southern California, Los Angeles, CA, USA; ^l Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA, USA; ^m Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ⁿ Department of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia; ^o Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands

Article info

Article history:

Accepted March 6, 2021

Associate Editor:

Guillaume Ploussard

Keywords:

Biomarker
 Blood test
 Budget impact
 Cost
 Cost-effectiveness
 Health economics
 Liquid biopsy
 Localised prostate cancer
 Tissue-based test
 Urine test

Abstract

Context: Several liquid- and tissue-based biomarker tests (LTBTs) are available to inform the need for prostate biopsies and treatment of localised prostate cancer (PCa) through risk stratification, but translation into routine practice requires evidence of their clinical utility and economic impact.

Objective: To review and summarise the health economic evidence on the ability of LTBTs to inform decisions on prostate biopsies and treatment of localised PCa through risk stratification.

Evidence acquisition: A systematic search was performed in the EMBASE, MEDLINE, Health Technology Assessment, and National Health Service Health Economic Evaluation databases. Eligible publications were those presenting health economic evaluations of an LTBT to select individuals for biopsy or risk-stratify PCa patients for treatment. Data on the study objectives, context, methodology, clinical utility, and outcomes were extracted and summarised.

Evidence synthesis: Of the 22 studies included, 14 were focused on test-informed biopsies and eight on treatment selection. Most studies performed cost-effectiveness analyses ($n = 7$), followed by costing ($n = 4$) or budget impact analyses ($n = 3$). Most (18 of 22) studies concluded that biomarker tests could decrease health care

* Corresponding author. University of Melbourne Centre for Cancer Research, 305 Grattan Street, Melbourne, VIC 3000, Australia. Tel. +61 3 85598585.
 E-mail address: maarten.ijzerman@unimelb.edu.au (M.J. Ijzerman).



costs or would be cost-effective. However, downstream consequences and long-term outcomes were typically not included in studies that evaluated LTBT to inform biopsies. Long-term effectiveness was modelled by linking evidence from different sources instead of using data from prospective studies.

Conclusions: Although studies concluded that LTBTs would probably be cost-saving or -effective, the strength of this evidence is disputable because of concerns around the validity and transparency of the assumptions made. This warrants prospective interventional trials to inform health economic analyses to ensure collection of direct evidence of clinical outcomes based on LTBT use.

Patient summary: We reviewed studies that evaluated whether blood, urine, and tissue tests can reduce the health and economic burden of prostate cancer. Results indicate that these tests could be cost-effective, but clinical studies of long-term outcomes are needed to confirm the findings.

© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Distinguishing between indolent and aggressive tumours remains a challenge in the diagnosis and management of localised prostate cancer (PCa). Existing clinical prognostic assays, such as digital rectal examination (DRE) and serum levels of prostate-specific antigen (PSA), have limited specificity and sensitivity for early identification of aggressive tumours. Together with the lack of comprehensive liquid biopsies in PCa care, this is leading to many tissue biopsies and repeat biopsies that have substantial cost and clinical complications, such as bleeding and infection, leading to major health and economic burdens on patients and society. Given that a minority of all PCas diagnosed represent life-threatening disease and that tissue biopsies have limited precision in predicting the clinical course of the disease, the health and economic burden for PCa patients and society is further increased by overdiagnosis that may lead to overtreatment [1,2].

To reduce the burden of PCa, prospective evidence suggests that patients with low and favourable intermediate risk PCa (PSA <10 ng/ml and Gleason $\leq 3 + 4$ [grade group 2]) may be managed through active surveillance (AS) [3,4]. The ProtecT study randomised 1643 patients with screen-detected PCa, of whom approximately 80% had low or favourable intermediate risk, to AS, radical prostatectomy, or radiotherapy as the initial management strategy [5]. After median follow-up of 10 yr, radical treatment reduced the risk of disease progression, but a significant difference in PCa-specific or overall survival was not observed. Despite these results and the common complications associated with radical treatments that substantially impact quality of life [5], several real-world studies have shown that only 30–50% of patients with low risk and 10–15% of those with intermediate risk are initially managed with AS in the USA, Germany, and Australia [6–10]. This suggests that both under- and overtreatment of PCa continue to pose a substantial health and economic burden on patients and society.

To better target treatment and to reduce the number of tissue biopsies, liquid and tissue-based biomarker tests

(LTBTs) have been developed to improve risk stratification of (suspected) localised PCa. These tests have two specific applications in the context of localised PCa by predicting whether patients harbour an aggressive tumour: (1) they indicate which patients should undergo a repeat biopsy after an initial negative biopsy and (2) they indicate which patients are candidates for AS and which are most likely to benefit from active treatment, such as radical or systemic treatment. Although several LTBTs are authorised on the basis of extensive validation studies and are commercially available, they have not yet been studied in prospective interventional trials and are not strongly recommended for localised disease in clinical guidelines of leading professional societies, such as the European Association of Urology, American Urology Association, and American Society for Clinical Oncology [3,11]. The National Comprehensive Cancer Network (NCCN) recommends consideration of biomarkers in selecting individuals for a prostate biopsy to improve the specificity of screening [12]. The NCCN does not recommend routine use of biomarkers for informing decisions on treatment, but suggests that patients with low- and favourable intermediate-risk PCa may consider use of the tissue-based Decipher, Oncotype Dx, and Prolaris tests during initial risk stratification [13].

In addition to evidence on the clinical utility of LTBTs in improving outcomes, health economic evidence is required to justify the costs of these tests to ensure successful translation to widespread clinical use. Many countries around the world, such as the UK, Canada, and Australia, require evidence on the cost-effectiveness or “value for money” of health care technologies before their use is reimbursed by public health care systems. Although recent clinical-evidence reviews of these tests have suggested the need to include cost-effectiveness [14–16], a formal appraisal of the health economic evidence for test-informed management of PCa is lacking. We sought to fill this gap and provide a basis for future study design enabling economic evaluations of LTBT by reviewing the current health economic evidence on the use of LTBTs to inform the need for a (repeat) biopsy or treatment decisions for localised PCa.

2. Evidence acquisition

The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [17,18]. A protocol for this review was not published before it was conducted.

2.1. Eligibility criteria

Eligible publications were those reporting on model- or trial-based health economic evaluations of a liquid- (including urine and blood) or tissue-based test to select individuals for a prostate biopsy or to risk-stratify patients with localised PCa for treatment. The study was not limited to full economic evaluations such as cost-benefit and -effectiveness analyses, and included costing studies (ie, cost per patient as the main outcome) and budget impact analyses (ie, population-level cost as the outcome). A test was considered to inform biopsies if it informed the decision to perform prostate biopsies in PCa patients or individuals who are suspected of having PCa based on PSA and DRE. This included the use of tests to inform the need for biopsies for patients on AS following diagnosis of a presumed clinically insignificant cancer. A test was considered to risk-stratify patients for treatment if it informed treatment decisions, including decisions regarding adjuvant treatment. Only full-text publications written in English were included. Publications investigating standard PSA only were not eligible for inclusion. Studies investigating PSA-based tests beyond standard PSA, such as percent free PSA and PSA density, were eligible for inclusion. Other publications not eligible for inclusion were those focusing on screening or metastatic disease, cost-of-illness studies, reviews, commentaries, letters, conference abstracts, and those evaluating management options only. No restrictions regarding the year of publication were applied.

2.2. Search strategy and study selection

The literature search was performed on September 16, 2020 using the Ovid platform to access the EMBASE, MEDLINE, Health Technology Assessment, and National Health Service Health Economic Evaluation Database platforms. Each database was searched individually using four sets of free-text terms to identify publications on (1) PCa, (2) economic evaluations, and (3) tests, and (4) to exclude publications on screening and metastatic PCa. Only generic terms were used to identify LTBTs; no specific biomarker or test names were used to avoid selection bias based on prior knowledge of certain biomarkers or tests. Subject headings were considered but were not included in the final search strategy. No exclusion criteria were enforced during the search to avoid erroneous exclusion of eligible publications. The final database-specific searches are presented in Supplementary Tables 1–4.

Two reviewers (K.D. and A.P.S.) independently screened titles and abstracts of 150 publications to check for consistency, after which one reviewer (K.D.) completed the screening. The full texts of included publications were

independently reviewed by the same two reviewers for final inclusion or exclusion. Disagreements between reviewers were resolved via consensus. Publications were excluded if they were not full-text articles (eg, conference abstract), not about PCa, not a health economic evaluation of a LTBT, or if they focussed on imaging only. The references of publications included were screened for further articles of interest.

2.3. Data extraction and synthesis

One reviewer (K.D.) extracted data from all the publications included using a predefined data extraction template. Information was extracted for year of publication, journal of publication, source(s) of funding, conflict(s) of interest, test(s) considered, test application (ie, inform biopsies or treatment), patient population, type of health economic analysis, health outcomes considered, strategies compared, study perspective, geographical location, type of analysis (ie, trial- or model-based), time horizon, cost indexing year, discount rates, modelling technique, model structure, model validation efforts, sensitivity analyses performed, uncertainty analyses performed, evidence approach, evidence for diagnostic performance, evidence for health outcomes, evidence for impact on clinical management, evidence on patient preferences, economic outcomes, and health outcomes.

In terms of data synthesis, journals of publication were classified according to their subject areas as medical, health policy, or multidisciplinary according to their subject area and category on SCImago Journal & Country Rank (www.scimagojr.com/). Potential conflicts of interests were determined according to the (industry) funding source and whether any author had industry or consultancy affiliations. The health economic analyses were categorised as costing, budget impact, or cost-effectiveness analyses, with multiple categories potentially applicable per publication. Comparators were classified as standard of care (SOC), including a test, or other (eg, when including imaging only). Health and economic outcomes were summarised according to whether test use increased or decreased costs and health outcomes and, for cost-effectiveness studies, whether their use was considered cost-effective by the original authors. Increases in health outcomes of less than 0.05 quality-adjusted life years (QALYs) were considered negligible increases. Although arbitrary, this threshold was selected and used to synthesise the evidence into a format informative to readers, in other words, to indicate whether the difference was considered meaningful. The threshold is not a measure of statistical significance, as significance would relate to the certainty rather than the magnitude of the difference in QALYs.

2.4. Risk of bias and quality of evidence

In the absence of an established method for assessing bias and methodological quality in health economic studies, the risk of bias in publications and the appropriateness of the methods was assessed as part of the evidence synthesis on the basis of the study methods and evidence used. The

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was used to assess the quality of reporting [19]. Although the CHEERS checklist was developed as a checklist rather than a quality scoring tool, it has been widely used to assess the quality of reporting for health economic studies in the absence of better alternatives. For each publication, we assessed which CHEERS items were applicable and whether those were reported. A score for the quality of reporting of a publication on a scale from 0% to 100% was defined as the proportion of applicable items reported compared to the total number of applicable CHEERS items.

3. Evidence synthesis

The literature search yielded 1535 publications, of which 317 were identified as duplicates (Fig. 1 and Supplementary Tables 1–4). Of the 1218 unique publications, 1140 were excluded on the basis of title and abstract. After assessment




Fig. 1 – PRISMA flowchart of the study selection process. HTA = Health Technology Assessment; NHSHEED = National Health Service Health Economic Evaluation Database.

of the full text of the remaining 78 publications, 58 were excluded for varying reasons, most commonly because of an inappropriate article format or because it was a study only evaluating multiparametric magnetic resonance imaging (mpMRI; Fig. 1). After adding two publications to the sample based on cross-referencing, the final number of publications included for data extraction was 22.

3.1. Characteristics of the studies included

Fourteen studies (64%) focused on the use of tests to inform biopsies [20–33], that is, whether an initial or repeat biopsy was to be performed, whereas eight studies (36%) focused on the use of tests for risk stratification to inform treatment decisions [34–41]. Tables 1 and 2 provide an overview of a subset of the data extracted for tests aimed at informing biopsies and treatment of PCa, respectively. An overview of all the data extracted is provided in Supplementary Tables 5 and 6. An overview of the tests evaluated and their characteristics is provided in Table 3. Note that one study considered a hypothetical test [32], which is not included in this table.

Tests were mostly evaluated for use in the USA (10/22 studies, 45%) [35,22,26–28,36–38,40,41], followed by France ($n = 3$, 14%) [23,30,31] and then Germany [21,30], Spain [20,30], and the UK [33,34] ($n = 2$, each, 9%). Canada [39], England and Wales [24], Hong Kong [29], Italy [30], The Netherlands [25], and Sweden [32] were each the perspective in one study. Nine studies (41%) reported industry funding [23,26,30,31,33–35,37,40]. Another six studies (27%) did not disclose any funding source [22,25,27,28,36,38], but three of these studies included authors with industry or consultancy affiliations [22,27,38]. Eleven studies (50%) were published relatively recently, from 2017 onwards. Most publications were in medical journals ($n = 15$, 68%) [20,21,25,27,28,30,31,33–35,37,38,40,41], followed by health policy journals ($n = 6$, 27%) [22–24,32,36,39] and multidisciplinary journals ($n = 1$, 5%) [29].

3.2. Quality of reporting

Detailed scoring of the studies according to the CHEERS checklist is presented in Supplementary Table 7. On average, the studies included reported 81% of the applicable items (median 80%, range 64–100%). CHEERS items that were not appropriately reported by 20% or more of the studies to which they were applicable included: title; setting and location; effectiveness measure; health-related quality-of-life population; currency and conversion; characterisation of uncertainty; source of funding; and conflicts of interest. On average, publications in health policy journals reported more CHEERS items (87%) compared to papers in medical and multidisciplinary journals (79%). Although this finding is concordant with previous reviews of health economic studies [42,43], lower completeness of reporting is not necessarily associated with lower methodological quality.

Table 1 – Overview of the data extracted for 14 health economic studies on liquid- or tissue-based tests to inform decisions on the need for a prostate biopsy

Publication	Analysis	Test(s) considered	DMA	Patient population	Comparison category	Health outcome	Geographical location	Evidence approach ^a	Diagnostic performance evidence	Impact of test(s) on costs	Impact of test(s) on health outcome	Cost-effectiveness judgement ^c
Bermudez-Tamayo et al, 2007 [20]	CEA	pfPSA	Initial Bx	Low risk	Test vs SOC	CCs detected, prognostic utility, actual cases	Spain	MBSS with observational cost data	Literature	Decrease	Decrease	Cost-effective
Schiffer et al, 2012 [21]	CA	UPA-PC	Initial Bx	Low risk or higher	Test vs SOC	NA	Germany	MBSS	Observational validation study	Decrease	NA	NA
Aubry et al, 2013 [22] ^b	BIA	ConfirmMDx	Repeat Bx	Repeat Bx candidate	Test vs SOC	NA	USA	MBSS	Observational validation study	Decrease	NA	NA
Malavaud et al, 2013 [23]	BIA	PCA3 Score	Repeat Bx	Repeat Bx candidate	Test vs SOC	NA	France	Chart review with simulated test results		Decrease	NA	NA
Nicholson et al, 2015 [24]	CEA	PCA3 Score, PHI	Repeat Bx	Repeat Bx candidate	Test vs SOC vs other	QALYs	England and Wales	MBSS with modelled impact	Observational validation studies	Increase	Negligible increase	Not cost-effective
Dijkstra et al, 2017 [25]	CEA	SelectMDx	Initial Bx	Low risk or higher	Test vs SOC	QALYs	Netherlands	MBSS	Observational validation study	Decrease	Negligible increase	Dominant
Sanda et al, 2017 [26]	CA	T2:ERG, PCA3 Score	Initial Bx	Low risk or higher	Test vs SOC vs other	NA	USA	MBSS	Observational validation study	Decrease	NA	NA
Voigt et al, 2017 [27] ^b	BIA	4Kscore	Initial Bx	Low risk or higher	Test vs SOC	NA	USA	Observational study with modelled impact		Decrease	NA	NA
Sathianathan et al, 2018 [28]	CEA	PHI, 4Kscore, SelectMDx, EPI	Initial Bx	Low risk or higher	Test vs SOC	QALYs	USA	MBSS	Observational validation studies	Decrease	Negligible increase	Cost-effective
Boutell et al, 2019 [29]	CEA	PHI	Initial Bx	Low risk	Test vs SOC	CCs missed, unnecessary Bx	Hong Kong	MBSS	Observational validation study	Decrease	Increase in CCs missed, decrease in unnecessary Bx	Inconclusive
Govers et al, 2019 [30]	CEA	SelectMDx	Initial Bx	Bx candidate	Test vs SOC	QALYs	France, Germany, Italy, Spain	MBSS	Observational validation study	Decrease	Negligible increase	Dominant
Mathieu et al, 2019 [31]	CA	PHI	Initial Bx	Low risk	Test vs SOC	NA	France	Observational study with MBSS	Observational validation study	Increase	NA	NA
Fridhammer et al, 2020 [32]	CEA	Hypothetical	Initial Bx	Low risk	Test vs SOC	QALYs	Sweden	MBSS	Assumption	Decrease (PSA 3.0–9.9 or 2.0–9.9 ng/ml)	Decrease (PSA 3.0–9.9 ng/ml) Increase (PSA 2.0–2.9 or 2.0–2.9 ng/ml)	Cost-effective
Kim et al, 2020 [33]	CA	PSAd, PHI	Initial Bx	Bx candidate	Test vs other	NA	UK	Observational study with modelled impact	Observational validation study	Decrease	NA	NA

BIA = budget-impact analysis; CA = cost analysis; CEA = cost-effectiveness analysis; DMA = decision-making aim; Bx = biopsy; NA = not applicable; PSA = prostate-specific antigen; pfPSA = percent free PSA; UPA-P = urinary proteome analysis for prostate cancer; PHI = Prostate Health Index; EPI = ExoDx Prostate Intelli-Score; PSAd = PSA density; SOC = standard of care; mpMRI = multiparametric magnetic resonance imaging; CCs = cancer cases; QALYs = quality-adjusted life years; MBSS = modelling based on sensitivity and specificity; DT = decision tree; STM = state-transition model; DES = discrete event simulation.

^a Impact here refers to both health and economic outcomes for CEAs and economic outcomes for CAs or BIAs.

^b Obtained via cross-referencing.

^c A dominant strategy improves health outcomes at lower costs, so it is better in terms of health and economic outcomes, whereas a cost-effective strategy improves health outcomes at higher costs, but the increase in costs is considered proportionate to the improvement in health, so the improvement in health is worth the increase in costs.

Table 2 – Overview of data extracted data for eight health economic studies on liquid- or tissue-based tests to facilitate treatment decisions for localised prostate cancer

Publication	Analysis	Test(s) considered	DMA	Patient population	Comparison category	Health outcome	Geographical location	Evidence approach ^a	Diagnostic performance evidence	Impact of test(s) on costs	Impact of test(s) on health outcome	Cost-effectiveness judgment ^b
Calvert et al, 2003 [34]	CEA	DNA-Ploidy	Initial TS	Localised NOS	Test vs other	QALYs	UK	Modelling based on sensitivity and specificity	Assumption	Increase	Increase	Cost-effective
Zubek and Konski, 2009 [35]	CEA	ProstatePc	Adjuvant TS	Received RP	Test vs SOC	QALYs	USA	OBS with modelled impact	NA	Increase	Increase	Cost-effective
Reed et al, 2014 [36]	CEA	NADiA ProVue Slope	Adjuvant TS	IR and HR of recurrence	Test vs SOC	QALYs	USA	Retrospective study with modelled impact	NA	Increase	Negligible increase	Not cost-effective
Roth et al, 2015 [37]	CEA	ProMark	Initial TS	LR and IR of recurrence	Test vs SOC	QALYs	USA	OBS with modelled impact	Observational validation study	Decrease	Negligible increase	Dominant
Albala et al, 2016 [38]	CA	OncotypeDX	Initial TS	Favourable IR or LR	Test vs SOC	NA	USA	OBS with historical cohort	NA	Decrease (LR) Increase (IR)	NA	NA
Health Quality Ontario, 2017 [39]	BIA	Prolaris	Initial TS	LR and IR	Test vs SOC	NA	Canada	OBS	NA	Increase	NA	NA
Lobo et al, 2017 [40]	CEA	Decipher	Adjuvant TS	Received RP	Test vs SOC vs other	QALYs	USA	OBS with clinical vignette study	NA	Increase	Increase	Cost-effective
Chang et al, 2019 [41]	CEA	OncotypeDX	Initial TS	Favourable IR or LR	Test vs SOC	QALYs	USA	OBS with historical cohort	NA	Increase	Increase	Cost-effective

BIA = budget-impact analysis; CA = cost analysis; CEA = cost-effectiveness analysis; DMA = decision-making analysis; TS = treatment strategy; NA = not applicable; NOS = not otherwise specified; RP = radical prostatectomy; HR = high risk; IR = intermediate risk; LR = low risk; SOC = standard of care; QALYs = quality-adjusted life years; OBS = observational study; DT: decision tree, STM: state-transition model.

^a Impact here refers to both health and economic outcomes for CEAs and economic outcomes for CAs or BIAs.

^b A dominant strategy improves health outcomes at lower costs, so it is better in terms of health and economic outcomes, whereas a cost-effective strategy improves health outcomes at increased costs, but the increase in costs is considered proportionate to the improvement in health, so the improvement in health is worth the increase in costs.

Table 3 – Overview of the liquid- and tissue-based biomarker tests evaluated in the health economic studies included in the review

Test name	Sample type	Biomarker(s)	DMA	Studies, n (%)	References
Prostate Health Index	Blood	Total PSA, free PSA, proPSA	Biopsy	5 (23)	[24,28,29,31,33]
PCA3 Score/PROGENSA	Urine	Relative levels of <i>PCA3</i> and <i>KLK3</i> RNA	Biopsy	3 (14)	[23,24,26]
SelectMDx	Urine	<i>DLX1</i> , <i>HOXC6</i> and <i>KLK3</i> mRNA (this test also considers clinical variables)	Biopsy	3 (14)	[25,28,30]
4Kscore	Blood	Total PSA, free PSA, intact PSA, and human glandular kallikrein 2	Biopsy	2 (9)	[27,28]
OncotypeDx	Tissue	mRNA levels of 12 cancer-related genes (and 5 reference genes) involved in stromal response, androgen signalling, cellular organisation, and proliferation	Treatment	2 (9)	[38,41]
ConfirmMDx	Tissue	Methylated <i>GSTP1</i> , <i>APC</i> , and <i>RASSF1</i>	Biopsy	1 (5)	[22]
Decipher	Tissue	mRNA levels of 22 genes involved in cell differentiation, proliferation, adhesion, motility, structure, cell-cycle progression, mitosis, immune modulation, and other unknown function	Treatment	1 (5)	[40]
DNA-Ploidy	Tissue	Amount of DNA in the nuclei of prostate cancer cells	Treatment	1 (5)	[34]
ExoDx Prostate Intelli-Score	Urine	Exosomal RNA for <i>PCA3</i> , <i>SPDEF</i> , and <i>ERG</i>	Biopsy	1 (5)	[28]
NADiA Prosvue Slope	Blood	Supersensitive PSA kinetics	Treatment	1 (5)	[36]
Percent free PSA	Blood	Free PSA, total PSA	Biopsy	1 (5)	[20]
Prolaris	Tissue	mRNA levels of 31 cell-cycle progression genes and 15 control genes	Treatment	1 (5)	[39]
ProMark	Tissue	Relative expression of 8 proteins (<i>CUL2</i> , <i>DERL1</i> , <i>FUS</i> , <i>HSPA9</i> , <i>PDSS2</i> , <i>SMAD4</i> , <i>S6(P)</i> , and <i>YBX1</i>)	Treatment	1 (5)	[37]
ProstatePx	Tissue	Morphometric and antigen expression profile of prostate cancer cells	Treatment	1 (5)	[35]
PSA density	Blood	Total PSA, prostate volume	Biopsy	1 (5)	[33]
T2:ERG	Urine	Relative levels of <i>TMPRSS2:ERG</i> and <i>KLK3</i> mRNA	Biopsy	1 (5)	[26]
Urinary proteome analysis	Urine	12 urinary peptides, total PSA, free PSA	Biopsy	1 (5)	[21]

DMA = decision-making aim; PSA = prostate-specific antigen.

3.3. LTBTs to inform the need for prostate biopsies

Of the 14 studies focusing on the use of tests to provide information on the need for a biopsy, 11 (79%) focused on the need for an initial biopsy [20,21,25–33] and three (21%) on the need for a repeat biopsy after an initial negative tissue biopsy [22–24]. Thirteen studies (93%) compared the use of a test to SOC, one of which also included a strategy without biopsies [26] and another additionally investigated the combination of tests [24]. One study compared several strategies including tests and imaging [33].

Most studies were cost-effectiveness analyses ($n = 7$, 50%) [20,24,25,28–30,32], followed by cost analyses ($n = 4$, 29%) [21,26,31,33] and budget impact analyses ($n = 3$, 21%) [22,23,27]. Five of the cost-effectiveness analyses used QALYs as the effectiveness outcome, which is the gold-standard effectiveness outcome in health economics as it allows for comparison across diseases. Twelve of 14 studies adopted a health care payer perspective. Nine studies (64%) considered a time horizon of 3 yr or shorter. All studies were model-based, with decision tree analysis the technique most frequently used ($n = 7$, 50%). Six studies considered treatments in their model structure [25–28,30,32]. No study presented model validation efforts. Three studies (21%) performed uncertainty analyses [24,28,32].

Eleven out of 14 studies (79%) modelled test outcomes and subsequent management decisions based on the sensitivity and specificity of the tests and linked those test outcomes to health and economic outcomes, whereas two

studies used observational data on diagnosis patterns and linked those to health and economic outcomes [27,33]. One study performed a chart review for which test results were simulated to estimate how many biopsies could have been avoided [23]. For the 12 studies that used sensitivity and specificity, ten derived the diagnostic performance from observational studies [21,22,24–26,28–31,33] and single studies derived this from literature [20] or made an assumption because they investigated a hypothetical test [32]. Of the seven cost-effectiveness analyses, effectiveness outcomes were modelled based on literature in six [20,24,25,28,30,32] and based on observational data in one study [29], although for that study the effectiveness outcome was not QALYs but the number of missed cancer cases and unnecessary biopsies. All studies assumed perfect compliance with the test recommendations, that is, clinician or patient preferences and practice variations were not considered.

Eleven out of 13 studies (85%) found the use of tests to be cost-saving [20–23,25–30,33], of which those performing cost-effectiveness analyses found the use of tests cost-effective or dominant, that is, preferable in terms of effectiveness and costs. Two of these 13 studies (15%) found that the use of tests would increase costs [24,31]. One of these was the only official health technology assessment report, concluding that the use of two tests (evaluated separately) was not cost-effective [24]. The study that evaluated a hypothetical test for different subgroups found mixed results, but overall concluded that use of a test would be cost-effective [32].

3.4. LTBTs to inform treatment decisions for confirmed PCa

Of the eight studies on the use of tests to inform treatment decisions, five (63%) focused on the initial treatment after diagnosis [34,37–39,41] and three (38%) on postprostatectomy adjuvant treatment [35,36,40]. Four studies (50%) focused on a low- and intermediate-risk population [37–39,41] and one study focused on an intermediate- and high-risk cohort [36], whereas others defined the population of interest as having undergone prostatectomy ($n = 2$, 25%) [35,40] or having localised disease ($n = 1$, 13%) [34]. Seven studies (88%) compared the use of a test to SOC [35–41], one of which also included a strategy in which all patients would receive adjuvant treatment [40]. One study compared a test-informed strategy to strategies in which all patients would either enrol in a surveillance strategy or undergo prostatectomy in the initial treatment phase [34].

Six of the eight studies were cost-effectiveness analyses (75%) [34–37,40,41] and single studies presented a budget impact [39] or costing analysis [38]. All cost-effectiveness analyses were performed using QALYs as the effectiveness outcome. All studies adopted a health care payer perspective. Single studies considered a time horizon of 180 d [38] or 5 yr [39], whereas all other studies considered a time horizon of 10 yr or more [34–37,40,41]. Seven of the eight studies (88%) were model-based, with state-transition modelling the technique most frequently used ($n = 6$, 86%) [34–37,40,41]. All state-transition models were structured according to health states, whereas the structure of the decision tree was mainly defined by the different treatment options. Three of the seven model-based analyses (43%) presented external validation for specific parts of the model [36,37,41]. Four of the eight studies (50%) performed some sort of uncertainty analysis [35,35,36,37,40].

Seven of the eight studies (88%) mainly used observational data to link health and economic outcomes to observed treatment decisions based on test results [35–41], whereas one study (13%) modelled test outcomes and subsequent treatment decisions based on the sensitivity and specificity of the test [34]. Of the studies using observational data, one used historical data for the control strategy [38]. All six cost-effectiveness analyses modelled effectiveness outcomes based on the literature. Two studies (25%) assumed perfect compliance with test recommendations [34,35], that is, clinician or patient preferences as a source of practice variation were not considered, which is not expected to be realistic. The other studies accounted for variation in following test recommendations in the real world, but to varying extents: five modelled treatment patterns as found in the observational data used [36–39,41] and one used a clinical vignette study in which participants stated what their choice would be in varying scenarios [40]. No study explicitly considered patient preferences regarding treatment options, but the observational data used in four studies do include this real-world variation [37,37,38,39,41].

Six of the eight studies (75%) found that use of a test would increase the total costs of care [34–36,39–41], one study (13%) found a decrease in costs [37], and one study

found cost savings for a low-risk cohort but an increase in costs for an intermediate-risk population [38]. All cost-effectiveness analyses found that LTBT use results in better health outcomes, although this increase was considered to be relatively small in magnitude for two studies by the reviewers [36,37]. Five of the six cost-effectiveness analyses found that use of tests was cost-effective or dominant [34,35,37,40,41], whereas one study found that test use was not cost-effective [36].

3.5. Discussion

We systematically reviewed 22 health economic studies evaluating 17 different molecular tests aimed at informing the need for a (repeat) biopsy or treatment decisions for localised PCa. Overall, these studies suggest that LTBT use to inform the need for prostate biopsies and the treatment of PCa can be either cost-saving or -effective. In particular, tests aimed at informing biopsy decisions were found to result in cost savings because of a lower number of prostate tissue biopsies performed. LTBT use to inform treatment decisions could potentially be cost-effective, that is, they improve health outcomes at an acceptable increase in cost, according to the authors. The encouraging results from these studies, however, do not align with the current uptake of tests in clinical guidelines or routine practice outside the USA. This discordance is likely to be caused by the absence of prospective interventional clinical studies on which health economic evaluations should be based. In addition, our review identified methodological challenges explaining why the current studies provide insufficient evidence for health care decision-makers to justify the incremental costs. These mainly relate to the short time horizons for which outcomes are evaluated, including how use of these tests will impact clinical management in subsequent stages of the disease, and several structural model assumptions.

The studies that evaluated LTBT use to inform the need for invasive tissue biopsies had a particularly narrow focus in terms of downstream health outcomes and costs. For example, most of these studies adopted short-term time horizons and ignored the impact of false-negative test results or accounted for it in a limited way. The clinical utility of LTBTs in changing management was not considered in these studies at all and only indirectly in some studies focusing on PCa treatment. Ignoring these aspects may result in cost-effectiveness estimates that are biased in favour of tests, as a previous modelling study in advanced PCa demonstrated that compliance with test results may have a substantial impact on health economic outcomes [44]. Although studies focusing on treatment of PCa overall more extensively accounted for downstream consequences, the number of studies was low and they focused on specific tests, leaving the overall judgement on the cost-effectiveness of tests in this context uncertain.

Given the lack of prospective comparative evidence, the studies reviewed can be considered early-stage health economic evaluations that are neither designed nor suitable for providing definitive evidence for reimbursement. Nevertheless, these early economic models can inform

further translation of tests and treatments by prioritising additional clinical studies [45]. Despite being early-stage evaluations, overall the studies appraised provided insufficient justification of the evidence, model structures, and techniques used. This is in line with other reviews of health economic studies in oncology [43,46]. Willis et al [47] reviewed five full economic evaluations of mpMRI for the diagnosis prostate cancer and found substantial heterogeneity in the questions posed, pathways modelled, and assumptions made. They concluded that there is a need for a better standard of reporting around key modelling assumptions and a wider range of sensitivity analyses to explore the impact of structural assumptions and to reflect uncertainty around data inputs for the model parameters. We suggest that transparent reporting may be even more important for early-stage analyses specifically, as these often require a larger number and intensity of assumptions based on more limited evidence. Previous studies have additionally discussed a deficiency of policies for health economic analyses, as well as a lack of reviewers with knowledge of health economics, urging journals to provide authors and reviewers with guidance on cost-effectiveness studies [42]. Given that the vast majority of studies included in this review were published in medical journals and that reporting quality was found to be lower in those journals compared to health policy journals according to the CHEERS checklist, this may have contributed to the lack of justification identified.

Despite the overall positive findings, the issues highlighted above suggest that health economic estimates may be overoptimistic and that, consequently, the cost-effectiveness of test-informed management of PCa is promising but warrants additional research through prospective interventional studies. The observation that three out of eight studies without industry involvement had an overall negative conclusion (38%) compared to only one out of 14 studies with clear industry involvement (7%) may further add to scepticism about the strength of the currently available health economic evidence. This also highlights the need for investigator-initiated clinical studies to strengthen the evidence base for long-term health outcomes. Although controlled interventional studies are as necessary for biomarkers as they are for pharmaceuticals from a health economic perspective, consideration should be given to appropriate regulatory protection to ensure investments are protected following positive study results.

To advance the translation of tests on the basis of health economic evidence, future studies should be aware of several opportunities, most of which relate to the perception that tests should not be considered in isolation but as part of the broader clinical pathway. First, economic evaluations should be considered from an early stage in the development process to collect as much relevant information along the way, which could reduce the number of assumptions that need to be made in the health economic evaluation. Second, studies focusing on the use of tests in the diagnostic process should collect data on how the test will be used in practice, or at least explore the impact of compliance to test results in sensitivity analyses, and

realistically account for downstream consequences of false-negative test results. Third, studies focusing on the management of PCa should at least aim to collect data on the impact on actual decisions made and consequent long-term health through observational studies. Fourth, uncertainty in outcomes should be explored and reported more transparently in terms of both model parameters and model assumptions and structure, rather than just in terms of one-way sensitivity analysis of selected parameters. Finally, studies should use existing reporting checklists, such as the CHEERS checklist [19], to improve reporting on health economic evaluations.

Further research could also investigate the potential of LTBTs to identify asymptomatic metastatic disease during the diagnostic process. Such early detection could lead to downstaging and, hence, better long-term health outcomes.

This review has certain limitations. Its findings are subject to publication bias, as not all studies may have been published, especially studies with negative findings regarding the cost-effectiveness of tests. The risk of publication bias is highlighted by the substantial number of conference abstracts that were excluded during full-text screening, as full-text publications may not have been pursued for studies with negative findings. The CHEERS checklist was used to appraise the reporting quality of publications in the absence of a better alternative, but this checklist was not designed to score publications and using it to do so may be considered subjective. In terms of data extraction, the lack of clear reporting and justification of methods, modelling assumptions, and analyses performed might have resulted in categorisations that readers or the authors of the original papers might not fully agree with. Finally, some studies presented a range of analyses that had to be summarised into a single cost-effectiveness judgement at the discretion of the reviewers.

4. Conclusions

This review found that most health economic studies concluded that LTBTs can be cost-saving or -effective when used to select individuals for prostate biopsies or to inform decisions on the treatment of confirmed localised PCa through risk stratification. These findings warrant further research through prospective interventional studies to provide robust data on clinical utility and long-term health outcomes that will be essential to strengthen the health economic evidence base. Such information will be crucial to optimise reimbursement of the most cost-effective tests by public health care systems so that outcomes can be improved for the broader population.

Author contributions: Koen Degeling had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: IJzerman.

Acquisition of data: Degeling, Pereira-Salgado.

Analysis and interpretation of data: Degeling, Pereira-Salgado, Corcoran, Boutros, Kuhn, IJzerman.

Drafting of the manuscript: Degeling.

Critical revision of the manuscript for important intellectual content: Pereira-Salgado, Corcoran, Boutros, Kuhn, IJzerman.

Statistical analysis: Degeling.

Obtaining funding: Corcoran, IJzerman.

Administrative, technical, or material support: None.

Supervision: IJzerman.

Other: None.

Financial disclosures: Koen Degeling certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Maarten J. IJzerman has received research support from Illumina Inc. for projects related to whole-genome sequencing and liquid biopsies. Paul C. Boutros sits on scientific advisory boards for BioSymetrics Inc. and Intersect Diagnostics Inc. Peter Kuhn is a royalty recipient, shareholder, and advisor of Epic Sciences. The remaining authors have nothing to disclose.

Funding/Support and role of the sponsor: This work was part of the PRECEPT program funded by the Prostate Cancer Research Alliance, which is a joint initiative between the Movember Foundation and the Australian Government. Peter Kuhn is supported by NCI Cancer Center support grant P30 CA014089.

Acknowledgments: The authors would like to acknowledge Ms. Julia S. Hofkes for her contribution to an initial version of this review.

Data sharing statement: All data generated or analysed during this study are included in this published article and its supplementary information files.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.euros.2021.03.002>.

References

- Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009;360:1310–9.
- Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360:1320–8.
- Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. *J Urol* 2018;199:683–90.
- Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer–2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. *Eur Urol* 2021;79:243–62.
- Hamdy FC, Donovan JL, Lane JA, et al. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. *Health Technol Assess* 2020;24:1–176.
- Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990–2013. *JAMA* 2015;314:80–2.
- Ingimarsson JP, Celaya MO, Laviolette M, Rees JR, Hyams ES. Trends in initial management of prostate cancer in New Hampshire. *Cancer Causes Control* 2015;26:923–9.
- Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. *Eur Urol* 2015;67:44–50.
- Ruseckaite R, Beckmann K, O’Callaghan M, et al. A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. *BMC Cancer* 2016;16:607.
- Löppenber B, Sood A, Dalela D, et al. Variation in locoregional prostate cancer care and treatment trends at commission on cancer designated facilities: a National Cancer Data Base analysis 2004 to 2013. *Clin Genitourin Cancer* 2017;15:e955–68.
- Egger SE, Rumble RB, Armstrong AJ, et al. Molecular biomarkers in localized prostate cancer: ASCO guideline. *J Clin Oncol* 2019;38:1474–94.
- Carroll PH, Mohler JL. NCCN guidelines updates: prostate cancer and prostate cancer early detection. *J Natl Compr Canc Netw* 2018;16 (5 Suppl):620–3.
- Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2019;17:479–505.
- Olleik G, Kassouf W, Aprikian A, et al. Evaluation of new tests and interventions for prostate cancer management: a systematic review. *J Natl Compr Canc Netw* 2018;16:1340–51.
- Fine ND, LaPolla F, Epstein M, Loeb S, Dani H. Genomic classifiers for treatment selection in newly diagnosed prostate cancer. *BJU Int* 2019;124:578–86.
- Becerra MF, Atluri VS, Bhattu AS, Punnen S. Serum and urine biomarkers for detecting clinically significant prostate cancer. *Urol Oncol*. In press. <https://doi.org/10.1016/j.urolonc.2020.02.018>.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009;6:e1000100.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
- Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. *Value Health* 2013;16:231–50.
- Bermudez-Tamayo C, Martin Martin JJ, Del Puerto Lopez Del Amo Gonzalez M, Perez Romero C. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4–10 ng/ml. *Urol Int* 2007;79:336–44.
- Schiffer E, Bick C, Grizelj B, Pietzker S, Schofer W. Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany. *Int J Urol* 2012;19:118–25.
- Aubry W, Lieberthal R, Willis A, Bagley G, Willis 3rd SM, Layton A. Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. *Am Health Drug Benefits* 2013;6:15–24.
- Malavaud B, Cussenot O, Mottet N, et al. Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France. *J Med Econ* 2013;16:358–63.
- Nicholson A, Mahon J, Boland A, et al. The clinical effectiveness and cost-effectiveness of the PROGENSA prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. *Health Technol Assess* 2015;19:1–191.
- Dijkstra S, Govers TM, Hendriks RJ, et al. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics – a decision analytical model. *BJU Int* 2017;120:659–65.

- [26] Sanda MG, Feng Z, Howard DH, et al. Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer. *JAMA Oncol* 2017;3:1085–93.
- [27] Voigt JD, Dong Y, Linder V, Zappala S. Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: overall cost savings and improved quality of care to the US healthcare system. *Rev Urol* 2017;19:1–10.
- [28] Sathianathen NJ, Kuntz KM, Alarid-Escudero F, et al. Incorporating biomarkers into the primary prostate biopsy setting: a cost-effectiveness analysis. *J Urol* 2018;200:1215–20.
- [29] Bouttell J, Teoh J, Chiu PK, et al. Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4–10 in Hong Kong. *PLoS One* 2019;14:e0215279.
- [30] Govers TM, Hessels D, Vlaeminck-Guillem V, et al. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. *Prostate Cancer Prostat Dis* 2019;22:101–9.
- [31] Mathieu R, Castelli C, Fardoun T, et al. Cost analysis of prostate cancer detection including the Prostate Health Index (PHI). *World J Urol* 2019;37:481–7.
- [32] Fridhammar A, Axelsson U, Persson U, Bjartell A, Borrebaeck CAK. The value of a new diagnostic test for prostate cancer: a cost-utility analysis in early stage of development. *Pharmacoecon Open* 2020;5:77–88.
- [33] Kim L, Boxall N, George A, et al. Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to Refine Mri) study. *BMC Med* 2020;18:95.
- [34] Calvert NW, Morgan AB, Catto JWF, et al. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. *Br J Cancer* 2003;88:31–5.
- [35] Zubek VB, Konski A. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment. *Mol Diagn Ther* 2009;13:31–47.
- [36] Reed SD, Stewart SB, Scales Jr CD, Moul JW. A framework to evaluate the cost-effectiveness of the NADiA ProVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer. *Value Health* 2014;17:545–54.
- [37] Roth JA, Ramsey SD, Carlson JJ. Cost-effectiveness of a biopsy-based 8-protein prostate cancer prognostic assay to optimize treatment decision making in Gleason 3 + 3 and 3 + 4 early stage prostate cancer. *Oncologist* 2015;20:1355–64.
- [38] Albala D, Kemeter MJ, Febbo PG, et al. Health economic impact and prospective clinical utility of Oncotype DX Genomic Prostate Score. *Rev Urol* 2016;18:123–32.
- [39] Health Quality Ontario. Polaris Cell Cycle Progression test for localized prostate cancer: a health technology assessment. *Ontario Health Technol Assess Ser* 2017;17:1–75.
- [40] Lobo JM, Trifiletti DM, Sturz VN, et al. Cost-effectiveness of the Decipher Genomic Classifier to guide individualized decisions for early radiation therapy after prostatectomy for prostate cancer. *Clin Genitourin Cancer* 2017;15:e299–309.
- [41] Chang EM, Punglia RS, Steinberg ML, Raldow AC. Cost-effectiveness of the Oncotype DX Genomic Prostate Score for guiding treatment decisions in patients with early stage prostate cancer. *Urology* 2019;126:89–95.
- [42] Leung HW, Chan AL, Leung MS, Lu CL. Systematic review and quality assessment of cost-effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer. *Ann Pharmacother* 2013;47:506–18.
- [43] Degeling K, Vu M, Koffijberg H, et al. Health economic models for metastatic colorectal cancer: a methodological review. *Pharmacoeconomics* 2020;38:683–713.
- [44] Degeling K, Schivo S, Mehra N, et al. Comparison of timed automata with discrete event simulation for modeling of biomarker-based treatment decisions: an illustration for metastatic castration-resistant prostate cancer. *Value Health* 2017;20:1411–9.
- [45] IJzerman MJ, Koffijberg H, Fenwick E, Krahn M. Emerging use of early health technology assessment in medical product development: a scoping review of the literature. *Pharmacoeconomics* 2017;35:727–40.
- [46] Bullement A, Cranmer HL, Shields GE. A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. *Appl Health Econ Health Policy* 2019;17:771–80.
- [47] Willis SR, van der Meulen J, Valerio M, Miners A, Ahmed HU, Emberton M. A review of economic evaluations of diagnostic strategies using imaging in men at risk of prostate cancer. *Curr Opin Urol* 2015;25:483–9.